Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum

Journal of Clinical Oncology

Volumn 15, Issue 10, 1997, Pages 3208-3213

  De Lena, Mario ^a   Lorusso, Vito ^a   Bottalico, Clementina ^a   Brandi, Mario ^a   De Mitrio, Alessandra ^a   Catino, Annamaria ^a   Guida, Michele ^a   Latorre, Agnese ^a   Leone, Bernardo ^a   Vallejo, Carlos ^a   Gargano, Giulio ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; LONIDAMINE; MELPHALAN; METHOTREXATE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MYALGIA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PRIORITY JOURNAL; STOMACH PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0013522965     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.10.3208     Document Type: Article

References (33)

1. Ozols RF, Young RC: Ovarian cancer. Chemotherapy of ovarian cancer. Semin Oncol 18:222-223, 1991
2. Seltzer V, Vogl S, Kaplan B: Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cisplatin or carboplatin in patients previously responding to this agent. Gynecol Oncol 21:167-176, 1985
3. Gore ME, Fryatt I, Wiltshaw E, et al: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207-211, 1990
4. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
5. Floridi A, Paggi MG, D'Atri S, et al: Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst 66:407-499, 1981
6. Floridi A, Lehninger A: Action of the antitumor and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria. Arch Biochem Biophys 226:73-83, 1983
7. 13C nuclear magnetic resonance studies. Cancer Res 55:2814-2821, 1995
8. Robins HI: Combined modality clinical trials for favorable B-cell neoplasms: Neoplasms plus whole body hyperthermia and/or total body irradiation. Semin Oncol 18:23-27, 1991
9. Rosbe KW, Brann TW, Holden SA, et al: Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother Pharmacol 25:32-36, 1989
10. Teicher BA, Herman TS, Holden SA, et al: Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Cancer Res 51:780-784, 1991
11. Savini S, Zoli W, Nanni O, et al: In vitro potentiation by lonidamine of the cytotoxic effect of Adriamycin on primary and established breast cancer cell lines. Breast Cancer Res Treat 24:27-34, 1992
12. Zupi G, Greco C, Laudonio N, et al: In vitro and in vivo potentiation by lonidamine of the antitumor effect of Adriamycin. Anticancer Res 6:1245-1250, 1986
13. Tomirotti M, Bernardo G, Epifani C, et al: Recovery of response to Adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients. Int J Oncol 3:213-217, 1993
14. Raaphorst GP, Ko D, Feeley MM, et al: The effect of lonidamine alone or in combination with cisplatin on in vitro growth and viability of lung squamous cell carcinoma cell lines. Anticancer Res 11:41-48, 1991
15. Silvestrini R, Zaffaroni N, Villa R, et al: Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 52:813-817, 1992
16. Leclaire R, Besner JG, Band P, et al: High-performance liquid chromatography of lonidamine in human plasma and urine. J Chromatogr B Biomed Appl 277:427-432, 1983
17. Newell DR, Mansi J, Hardy J, et al: The pharmacokinetics of oral lonidamine in breast and lung cancer patients. Semin Oncol 18:11-17, 1991
18. Bottalico C, Micelli G, Guerrieri A, et al: An on-line semiautomated solid-phase extraction procedure for high-performance liquid chromatographic determination of lonidamine in serum. J Pharm Biomed Anal 13:1349-1353, 1995
19. WHO: Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979
20. Szekely JG, Lobreau AU, Delaney S, et al: Morphological effects of lonidamine on two human tumor cell culture lines. Scand J Electr Microsc 3:681-693, 1989
21. De Martino C, Malorni W, Accinni L, et al: Cell membrane changes induced by lonidamine in human erythrocytes and T-lymphocytes, and Ehrlich ascites tumor cells. Exp Mol Pathol 46:15-30, 1987
22. Floridi A, Gambacurta A, Bagnato A, et al: Modulation of Adriamycin uptake by lonidamine in Ehrlich ascites tumor cells. Exp Mol Pathol 49:421-431, 1988
23. De Martino C, Battelli T, Paggi MG, et al: Effects of lonidamine on murine and human tumor cells in vitro. A morphological and biochemical study. Oncology 41:15-29, 1984
24. Arancia G, Malorni W, Crated Trovalusci P, et al: Differential effect of lonidamine on the plasma membrane ultrastructure of normal and leukemic human lymphocytes. Exp Mol Pathol 48:37-47, 1988
25. Calabresi F, Marolla P, De Lauro L, et al: Lonidamine as potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study. Int J Oncol 4:753-760, 1994 (suppl 4)
26. Dogliotti L, Berruti A, Buniva T, et al: Lonidamine significantly increases the activity of epirubicin in advanced breast cancer patients. Results from a multicenter prospective randomized trial. J Clin Oncol 14:1165-1172, 1996
27. Frassineti GL, Nanni O, Lombardi A, et al: Lonidamine in modulation of response to Adriamycin in advanced breast cancer. Preliminary results. Int J Oncol 4:741-746, 1994
28. Pacini P, Algeri R, Rinaldini M, et al: FEC (fluorouracil, epirubicin and cyclophosphamide) versus EM (epirubicin and mitomycin-C) with or without lonidamine as first line treatment for advanced breast cancer. A multicentric randomized study. Preliminary report. Int J Oncol 4:761-766, 1994
29. Lorusso V, Catino AM, Brandi M, et al: Cyclophosphamide, mitoxantrone and fluorouracil versus cyclophosphamide, mitoxantrone and fluorouracil plus lonidamine for the treatment of advanced breast cancer. A multicentric randomized clinical trial. Int J Oncol 4:767-722, 1994
30. Gadducci A, Brunetti I, Muttini MP, et al: Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. Eur J Cancer 10:1432-1435, 1994
31. Lopez M, Vici P, Di Lauro L, et al: Intrapatient comparison of single agent epirubicin with or without lonidamine in metastatic breast cancer. Eur J Cancer 31A:1611-1614, 1995
32. De Lena M, De Mitrio A, Catino A, et al: Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results. Int J Oncol 4:779-782, 1994
33. Besner JG, Leclair R, Band PR, et al: Pharmacokinetics of lonidamine after oral administration in cancer patients. Oncology 41:48-52, 1984 (suppl 1)